GIP and diabetes mellitus: In vivo, intravenous infusion of GIP suppresses serum C-terminal telopeptide of type I collagen (CTX-1) levels, a biochemical marker reflecting the rate of osteoclastic bone resorption in patients with diabetes and their healthy counterparts [21,22,23].